Year: 2025

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal study Preliminary efficacy data demonstrate achievement of definition of remission in SLE (DORIS) in 83% of patients and complete renal response (CRR) in 50% of patients; all responses and remissions are ongoing with no evidence of disease activity at a median follow-up of 8.9 months All patients had refractory lupus nephritis; 4/6 patients had significantly impaired kidney function Patients received no other lupus directed therapy; steroids were tapered in all patients to 5mg by month six Company remains on track to dose first patient in Phase 2 trial in lupus nephritis (LN) by year-end 2025LONDON and GAITHERSBURG, Md., Oct....

New York, NY, Oct. 27, 2025 (GLOBE NEWSWIRE) — Chijet Motor Company, Inc. (NASDAQ: CJET) (“Chijet” or the “Company”) today announced the successful closing of a private placement offering of units, consisting of ordinary shares and warrants, for gross proceeds equivalent to $300 million in cryptocurrency. The offering was conducted with select non-U.S. institutional investors. Each unit comprises one ordinary share (par value $0.003) priced at the equivalent of $0.10 per share in cryptocurrency, based on prevailing market rates at the time of the transaction, and three warrants, each exercisable to purchase one ordinary share at an exercise price equivalent to $0.12 per share in cryptocurrency. The warrants are exercisable for three years from the date of issuance and may be exercised on a cashless basis under certain conditions,...

SEOUL, South Korea, Oct. 27, 2025 (GLOBE NEWSWIRE) — DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, announced today that it will release its 2025 third quarter financial results after the market closes on Monday, November 10, 2025, and host a conference call and simultaneous webcast at 5:00 p.m. ET (2:00 p.m. PT) that day. Both the call and webcast are open to the general public. On the call, DoubleDown management will review the Company’s financial results and provide a business update, followed by a question-and-answer session. To access the call, please use the following link: DoubleDown Third Quarter 2025 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits Neumora plans to provide a comprehensive M4 franchise update by mid-2026 WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898. Neumora’s M4 franchise comprises two highly potent and selective M4 muscarinic receptor positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, that may offer an improved therapeutic profile for schizophrenia...

WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2025 and provide an update on recent developments in its business after market close on Wednesday, November 5, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, November 6, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Investors section of Aquestive’s website at: Third Quarter 2025 Earnings Call Following the...

NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction  NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading weight loss driven by best-in-class pharmacology and brain penetration of NMRA-215 Neumora plans to initiate Phase 1 clinical study in the first quarter of 2026 WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor from three diet-induced obesity (DIO) mouse studies. NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like...

DAYTONA BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) — J. Powell Brown, president and chief executive officer, and Julie Turpin, chief people officer, are proud to announce that Brown & Brown, Inc. (“Brown & Brown”) and our team of U.S. companies have been Certified™ by Great Place to Work® for the seventh consecutive year. Additionally, our companies in Canada and the U.K. have been Certified™ for the first time. Our U.S. companies have also been included on the 2025 Fortune Best Workplaces for Women™ List for the fifth year.  Brown shared, “Our teammates are the heart of Brown & Brown. They’re the reason we’re a Great Place to Work™, and we’re fired up that our teams in Canada and the UK are now part of that recognition. Being named a Best Workplace for Women™ shows how serious...

Stockholders to Receive $2.25 Per Share of Common Stock in Cash, Representing the Highest Premium Paid for a public, exchange-traded REIT in Past Five Years WILLIAMSBURG, Va., Oct. 27, 2025 (GLOBE NEWSWIRE) — Sotherly Hotels Inc. (Nasdaq: SOHO) (“Sotherly” or the “Company”) today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with a joint venture led and sponsored by affiliates of Kemmons Wilson Hospitality Partners, LP (“KWHP”), with Ascendant Capital Partners LP (“Ascendant”) serving as a strategic joint venture partner (collectively, the “Joint Venture”), under which the Joint Venture entity, KW Kingfisher LLC, will acquire all outstanding shares of Sotherly common stock for $2.25 per share in cash (the “Merger Consideration”). The Merger Consideration represents a premium of 152.7%...

Returns 4.1 g/t Au (uncut) over 25.8 metres (core length) below current resource TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Wesdome Gold Mines Ltd. (TSX:WDO, OTCQX:WDOFF) (“Wesdome” or the “Company”) is pleased to announce a new mineralized zone at the Dubuisson deposit, located east of the Kiena Deep deposit at the Company’s 100% owned Kiena Mine Complex in Val-d’Or, Québec. The new zone has been intersected by drill hole DB-25-068, returning 4.1 g/t Au (uncut) over 25.8 metres (core length). Located approximately 100 metres below, and lateral to, the Dubuisson North Zone and currently interpreted to be between the Dubuisson North and South zones, this new zone represents a compelling opportunity to expand the Dubuisson deposit at depth. The combined grade and thickness are particularly encouraging, as the intercept highlights...

Robust balance sheet with access to over A$86.3M in funding comprising of, A$17.5M in cash, US$43.4M (A$65.5M) 24 month award from the U.S. Department of War to support antimony production in Alaska, and approximately ~A$3.3M in liquid investments and in the money warrants 2025 drill and surface exploration programs completed with assay results pending Melbourne, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) — Nova Minerals Limited (“Nova” and the “Company”) (NASDAQ: NVA) (ASX: NVA), (FRA: QM3), a gold and critical minerals exploration and development stage company focused on advancing the Estelle Gold and Critical Minerals Project in Alaska, U.S.A. provides its quarterly activities and cashow report for the quarter ended September 30, 2025   Highlights Estelle ProjectThe September 2025 quarter was another highly active period for...